Ann: Investor Presentation, page-112

First 112 Last

Share
Profile

Follow
jeans_sammy

13,333 Posts.

93

01/12/16

16:58

Post #: 21036386
Share

Originally posted by Lefevre ↑

Good to finally meet you Bonkers !
Impressive presentation. I could understand every word. Everything was clear and concise.
The path forward for sales is well structured and clear.

I liked the hearing aid comparison. Once you take the Cochlear implant out you still have the same hearing problem. Mente autism is the same. Once you stop using the headband the child will go back to his old ways.

Over 200 users currently. Some started 4 to 5 years ago. The information being gathered by recording electro physiological changes to the brain as opposed to a psychologist subjective observations is extremely valuable. They have already been approached from a couple of organisations about obtaining this data. This data will obviously be magnified in coming years with the huge step up in usage and its monetisation (don't think they have worked exactly how to yet) will be a key revenue source.

The commercial officer has hit the ground running and I would be expecting some fast results.
Their is a regulatory officer also appointed to deal with regulations on a global scale.
FDA trials about to start with the prestigious Carrick Institute which is a world leader in clinical neuroscience. The fact such a prestigious institute has taken these trials on is huge validation. I know from my RAP experience that these quality institutions only take on what they know will work and have a huge benefit to society.

In 2017 they will be finalising Mente pro and Mente Suite by the 4th quarter. Mente pro is a Clinical grade, medical device for clinical & research use. They already have hospitals waiting for this product.

I would like to say that Mente is a disruptive product but I can't because there is nothing to disrupt as there is no other product in this space.

The feeling I get is all the targets and deadlines they have set for next year are conservative and they aim to be ahead of each one.

With FDA approval in mid 2017, a growing sales pipeline, a product in the right space and the right capital structure NTI is set to really take off.

Cheers

Expand

Thanks @Lefevre, @bonkers89 and all who attended AGM in syd. Wanted join but had something from family scheduled. Missed opportunity to meet u all. Next AGM .

Did they really use example of Cochlear implant, if so then my resesrch and comparision along with COH chart (yesterday or day before) was pretty much in line and I still believe having such caliber team, we can slowly succeed in our field of Neuro Techs.

BTW - who was the last min buyer of $45K shared .

Cheers
J

NTI Price at posting: 46.0¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

RCE

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

There are more pages in this discussion • 9 more messages in this thread...

First 112 Last

Add NTI (ASX) to my watchlist

(20min delay)
Last 7.0¢		Change -0.002(2.78%)		Mkt cap ! $71.21M

Open	High	Low	Value	Volume
7.3¢	7.3¢	7.0¢	$86.59K	1.228M

Buyers (Bids)

No.	Vol.	Price($)
1	6000	7.1¢

Sellers (Offers)

Price($)	Vol.	No.
7.5¢	72226	1

View Market Depth

No.	Vol.	Price($)
2	138838	0.070
2	62535	0.069
1	973610	0.068
2	159208	0.067
1	150000	0.066

Price($)	Vol.	No.
0.075	72226	1
0.076	100000	1
0.077	116800	2
0.078	94680	3
0.079	300000	1

Last trade - 15.38pm 28/06/2024 (20 minute delay)

NTI (ASX) Chart

Ann: Investor Presentation, page-112

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Presentation, page-112

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News